Group 1: Financial Performance - In Q1 2025, the company achieved revenue of 31,566.22 million RMB, a year-on-year increase of 43.52% [5] - The net profit attributable to shareholders was -1,275.65 million RMB, a reduction in losses by 72.01% compared to the previous year [5] - The company has distributed approximately 192 million RMB in dividends over the past five years, but will not distribute profits for the fiscal year 2024 due to ongoing project investments and significant expenditures [6] Group 2: Research and Development - The company holds a total of 237 patents, including 122 invention patents, which account for 51.5% of the total [2] - In 2024, the company applied for 33 new patents and received 19 authorizations, including 5 invention patents [2] - The company is enhancing its production efficiency through the implementation of microchannel continuous flow technology, which has received positive feedback from safety authorities [2] Group 3: Strategic Outlook - The company aims to optimize its product structure and expects its main CDMO business to recover in 2025, marking a new development opportunity [4] - The company is focusing on innovation in agriculture and pharmaceuticals, integrating deeply into global supply chains to enhance sustainable development capabilities [3] - Future growth drivers include continuous manufacturing, biocatalysis, and AI-driven R&D, which are expected to provide competitive advantages in the global market [4] Group 4: Market and Operational Challenges - The company faced challenges in 2024 due to industry cyclicality, market competition, and asset impairment, impacting its performance [6] - The management is committed to improving operational resilience by focusing on core business optimization, technology innovation, and cost control [6] - The company is currently in the planning stage for potential acquisitions, with no formal agreements signed yet [6]